{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shroff R"],"funding":["Kidney Research UK","National Institute for Health Research (NIHR)","NIH"],"pagination":["1114-1127"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5837664"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(7)"],"pubmed_abstract":["In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children wi"],"journal":["Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association"],"pubmed_title":["Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis."],"pmcid":["PMC5837664"],"funding_grant_id":["RP39/2013","CDF-2016-09-038","KKR/Paed2017/01","ICA-CDRF-2016-02-057"],"pubmed_authors":["Bacchetta J","Bakkaloglu S","European Society for Paediatric Nephrology Chronic","Stefanidis CJ","Wan M","Ariceta G","Klaus G","Nagler EV","Edefonti A","Schmitt CP","Cozzolino M","Shroff R","Haffner D","Vande Walle J"],"additional_accession":[]},"is_claimable":false,"name":"Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.","description":"In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active vitamin D therapy in children wi","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2025-04-04T14:48:41.472Z","creation":"2025-04-04T14:48:41.472Z"},"accession":"S-EPMC5837664","cross_references":{"pubmed":["28873971"],"doi":["10.1093/ndt/gfx080"]}}